Codexis

Codexis OpEx/Revenue

The Operating Expenses to Revenue Ratio of Codexis (CDXS) as of Nov 5, 2026 is 141.19 %. In the previous year, Operating Expenses to Revenue Ratio was 170.88 % — a change of -17.38% (lower).

OpEx/Revenue

141.19 %

YoY

-17.38%

Last updated:

Operating Expenses to Revenue Ratio of Codexis is 2025 141.19 % . Operating Expenses to Revenue Ratio of Codexis was 2024 170.88 % . It decreases by -17.38% lower compared to the previous year.

The Codexis OpEx/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OpEx/Revenue
Date
OpEx/Revenue
Jan 1, 2018
97.81 USD
Jan 1, 2019
95.50 USD
Jan 1, 2020
114.74 USD
Jan 1, 2021
100.47 USD
Jan 1, 2022
95.22 USD
Jan 1, 2023
159.44 USD
Jan 1, 2024
170.88 USD
Jan 1, 2025
141.19 USD
The Codexis OpEx/Revenue history
YEAROpEx/RevenueYoY
141.19 %-17.38%
170.88 %+7.18%
159.44 %+67.44%
95.22 %-5.22%
100.47 %-12.44%
114.74 %+20.15%
95.50 %-2.37%
97.81 %-16.60%
117.28 %+20.20%
97.57 %-5.12%
102.83 %-18.76%
126.58 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Codexis Stock analysis

What does Codexis do? Codexis Inc. is an American biotechnology company that specializes in developing innovative biological solutions for a variety of industries. The company was founded in 2002 and is headquartered in Redwood City, California. Business Model: Codexis is service-oriented and provides customized enzyme solutions for companies looking to improve their products through sustainable processes. The company has developed a unique platform called Rational Protein Engineering, which allows for the development of specific enzymes for various industries. Customers benefit from enzyme optimization expertise and know-how. Divisions: Codexis operates in the fields of life sciences, materials science, agrochemicals, and biofuels. 1. Life Sciences: Codexis specializes in the production of enzymes and biocatalysts for the pharmaceutical industry in the life sciences division. The goal is to provide a faster and more efficient manufacturing process for pharmaceutical active ingredients. The company has successfully developed active ingredients for antibodies, lipids, uric acid, and antivirals. 2. Materials Science: In the materials science division, Codexis specializes in the production of enzymes for materials such as dyes, polymers, and cosmetic products. Codexis ensures that these products are efficiently manufactured without the use of environmentally harmful chemicals. 3. Agrochemicals: Codexis offers customized enzyme solutions to agrochemical manufacturers that reduce the use of chemicals and benefit the environment. These enzymes help in the production of pesticides and other agrochemicals. 4. Biofuels: In the biofuels division, Codexis specializes in the production of enzymes for processing corn, harvested plants, or waste products. These enzymes help enable cost-effective biofuel production. Products: Codexis has developed a wide range of products tailored to the needs of various industries. Some of the products recently introduced to the market by Codexis include: 1. CodeEvolver: CodeEvolver is a platform that allows biotechnology companies to quickly create customized enzyme solutions for their specific needs. The process is fully automated and results in a significant reduction in development time and costs. 2. Codex® screening panels: Codexis offers various screening panels that allow customers to quickly and efficiently select the enzymes best suited for their purposes. The panels are suitable for industries including pharmaceuticals, chemicals, and plant protection. 3. Codex® enzymes: Codexis offers a wide range of enzymes specifically designed for different industry needs. This includes enzymes for the production of biofuels, pesticides, cosmetic products, and pharmaceuticals. Overall, Codexis Inc. has demonstrated its ability to deepen the understanding of biocatalysts and introduce innovative biological processes in a variety of industries through its unique Rational Protein Engineering platform. Codexis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Codexis stock

Operating Expenses to Revenue Ratio of Codexis is 141.19 % in 2025.

Operating Expenses to Revenue Ratio of Codexis changed from 170.88 % to 141.19 %, representing a -17.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Expenses to Revenue Ratio Codexis since 2006 – with annual values, charts, and detailed analysis.

The OpEx/Revenue ratio measures total operating expenses as a percentage of revenue. Declining ratios suggest improving operational leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Expenses to Revenue Ratio's Codexis with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Expenses to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Expenses to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Codexis

All Key Metrics — Codexis